Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

October 25th 2024

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

FDA Grants Fast Track Designation to HC-7366 in Relapsed/Refractory AML

October 25th 2024

HC-7366 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

October 25th 2024

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

October 24th 2024

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer

October 24th 2024

Sung Gwe Ahn, MD, PhD, discusses survival outcomes with ovarian function suppression-based endocrine therapy based on the HERA trial in HR-positive, HER2-positive breast cancer.

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

October 24th 2024

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

October 24th 2024

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

October 23rd 2024

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

October 23rd 2024

177Lu-PNT2002 improved radiographic progression-free survival in PSMA-positive mCRPC after progression on an ARPI.

SC Daratumumab Plus VRd Earns EU Approval in Newly Diagnosed, Transplant-Eligible Myeloma

October 23rd 2024

The European Commission has approved daratumumab plus bortezomib, lenalidomide, and dexamethasone in ASCT-eligible, newly diagnosed multiple myeloma.

Fadraciclib Demonstrates Safety, Early Efficacy Signals in CDKN2A/B+ Advanced Solid Tumors

October 23rd 2024

Fadraciclib was safe and showed signs of efficacy in advanced solid tumors harboring CDKN2A/B alterations.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML

October 22nd 2024

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.

TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors

October 22nd 2024

The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma

October 18th 2024

The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Botensilimab Plus Balstilimab Elicits Durable Responses in Refractory Metastatic Sarcoma

October 18th 2024

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.